Status:
UNKNOWN
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Gastro-enteropancreatic Neuroendocrine Tumor
Health Care Costs
Eligibility:
All Genders
15-100 years
Brief Summary
Neuroendocrine tumours (NETs) are rare and include a heterogeneous group of neoplasms derived from the endocrine system found in the gastrointestinal tract, pancreas and lung. Gastroenteropancreatic (...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of well-differentiated metastatic neuroendocrine tumour (either synchronous or metachronous)
- Diagnosis performed between 1 January 1990 and 31 December of 2017
- Patients seen at least once at the oncologic department of Hospices Civils de Lyon.
Exclusion
- Poorly differentiated neuroendocrine carcinoma
- Histologic mixed neuroendocrine tumour
Key Trial Info
Start Date :
July 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
880 Patients enrolled
Trial Details
Trial ID
NCT03863106
Start Date
July 15 2017
End Date
July 1 2020
Last Update
March 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Lyon, France, 69003